liveBook · Manning

Kinase inhibitor

As explained in Build AI Drug Discovery Pipelines

A kinase inhibitor is a compound that reduces the catalytic or signaling activity of a kinase.

A kinase inhibitor is a compound that reduces a kinase’s catalytic or signaling activity. Kinases transfer phosphate groups from ATP to substrate proteins; that modification changes protein shape and can activate or deactivate signaling pathways. section 8.1.1

Kinases are important small-molecule drug targets in cancer and inflammatory disease. Inhibiting an enzyme can prevent its substrate from becoming a product, but suppressing a kinase may also alter many downstream cellular processes. section 8.1.1 section 1.4.1

Effective kinase-inhibitor design must balance several practical requirements:

  • Achieve sufficient affinity for the intended kinase target. section 8.1.1
  • Maintain selectivity across the wider kinase family, because related kinases can share highly similar binding sites. section 8.1.1 section 1.4.1
  • Control off-target promiscuity, especially when compounds bind the conserved ATP-binding site. section 8.1.1
  • Use computational methods when routine experimental testing against every kinase is prohibitively expensive. section 8.1.1

An enzyme-inhibition analogy

COX-1 and COX-2 produce signaling molecules involved in inflammation. NSAIDs relieve pain by inhibiting these enzymes rather than blocking receptors, although excessive COX suppression can cause side effects. section 1.4.1

Figure 8.2 Map of human protein kinases, i.e., the Manning kinome tree, clustered based on sequence similarity into eight major groups [3].

Use the kinome tree to inspect how human protein kinases cluster into eight major sequence-similarity groups and where approved drug targets are distributed. section 8.1.1

How Build AI Drug Discovery Pipelines covers it

How deep it goes
Explains phosphorylation, signaling consequences, affinity, selectivity, ATP-site promiscuity, and computational motivation without detailing specific algorithms.
Examples
Uses COX inhibition by NSAIDs and the human kinome tree to illustrate enzyme inhibition, therapeutic tradeoffs, and kinase-family coverage.
What it assumes
Defines enzymes, ATP phosphorylation, substrates, products, ligands, agonists, and antagonists before applying them to kinase inhibition.
What you can do after
Evaluate kinase-inhibitor opportunities by comparing target affinity, kinase-family selectivity, off-target risk, and computational testing cost.
How it connects
Connects protein kinases with ATP, enzymes, phosphorylation, signaling pathways, ligands, receptors, drug design, and off-target effects.

Related concepts

This explainer was generated by Manning's knowledge graph from the text of Build AI Drug Discovery Pipelines. The section links point to the parts of the book it draws on.